Deprescribing antihypertensive medication is not associated with the risk for hospitalization for myocardial infarction (MI) ...

Research on hormone therapy reveals critical insights into cardiovascular disease risks, guiding clinicians in selecting ...

A new study supports previous data demonstrating the superiority of prasugrel over ticagrelor in reducing the composite outcome of mortality, myocardial infarction, or stroke in patients with acute ...

Sirius Therapeutics today announced that preliminary data from its Phase 1 clinical trial of SRSD107, a next generation siRNA ...

After more than a decade of research, experts have revealed a worrying reality for people taking certain hormone medications ...

研究者Sanjit Jolly博士说道，尽管安体舒通并不能减少心脏病发作后参与者的死亡和其它主要的心脏并发症，但其确实能降低机体发生心力衰竭的可能性，这对于患者和卫生保健专业人员而言或许是一项重要发现。参与者在这项临床试验中的表现要比之前好得多，这就反映了 血管 成形技术宅心脏病发作的整体护理中取得的进步，如今，包括药物、支架技术和更及时的干预策略等现代治疗方法常常能给患者的预后产生积极的影响结果 ...

In the CLEAR SYNERGY trial, routine spironolactone after myocardial infarction did not reduce cardiovascular AEs in patients ...

Philippine Health Insurance Corporation (PhilHealth) announced on Monday new benefit packages covering various illnesses as ...

Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein ...

In this randomized controlled trial, among patients with a history of myocardial infarction (MI), interruption of long-term ...